Myxredlin™ (insulin human in sodium chloride) – New drug approval

- On June 20, 2019, the FDA approved Celerity Pharmaceuticals' Myxredlin (insulin human in sodium chloride), to improve glycemic control in adults and pediatric patients with diabetes mellitus.
- Myxredlin is an intravenous (IV) administered short-acting human insulin.
    - Other short-acting human insulins include Humulin R® and Novolin R®. Both of these formulations can be administered IV or subcutaneous.
- Myxredlin is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin human or any of the excipients in Myxredlin.
- Warnings and precautions for Myxredlin include hyperglycemia or hypoglycemia with changes in insulin regimen, hypoglycemia, hypersensitivity and allergic reactions, hypokalemia, and fluid retention and heart failure with concomitant use of PPAR-gamma agonists.
- The most common adverse reactions with insulin human injection use were hypoglycemia, allergic reactions, weight gain and edema.
- The recommended dose of Myxredlin should be individualized and the dosage should be adjusted based on the individual's metabolic needs, blood glucose monitoring results, and glycemic control goal.
    - Myxredlin should be administered IV only under medical supervision with close monitoring of blood glucose and potassium levels.
- Celerity Pharmaceuticals launch plans for Myxredlin are pending. Myxredlin will be available in a single-dose container of 100 units insulin human in 100 mL of 0.9% sodium chloride (1 unit/mL).